A novel nutritional approach to infants and children with congenital diarrhea due to homozygous DGAT1 mutations
Journal of Pediatric Gastroenterology and Nutrition · 2024-08 · 79 (2) · 250-258
DOI: 10.1002/jpn3.12241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 27.06.2024. Verfasst von Peri Millman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hadassah, Pediatric Gastroenterology, Jerusalem, Israel. Hauptthemen laut MEDLINE: Diacylglycerol O-Acyltransferase, Diarrhea. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: None.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Diacylglycerol acyltransferase (DGAT) catalyzes the final step in triglyceride synthesis. DGAT1 is expressed in human enterocytes and is essential for fat absorption. Homozygous DGAT1 deficiency often presents with severe diarrhea and protein‐losing enteropathy (PLE) in the 1st weeks of life. Because severe restriction of fat intake controls diarrhea and decreases PLE, total parenteral nutrition (TPN) was the initial standard therapy in infants and children. We present tertiary center experience managing infants and children with DGAT1 deficiency resulting in the development of a nutritional approach that minimizes the use of TPN.
Methods
From 2014 to 2020, 12 infants with DGAT1 deficiency were treated. Stool output, growth, and development, as well as essential fatty acid status, were monitored. This retrospective experience formed the basis for treatment recommendations, which include an ultralow fat formula with intermittent peripheral intravenous lipid infusions during the 1st year of life.
Results
All patients with prolonged intestinal fat exposure had PLE, which resolved when treated with the nutrition protocol. Essential fatty acid status as measured by triene:tetraene ratios normalized in all treated patients. Over time, early genetic diagnosis and prompt initiation of an ultralow fat diet with peripheral intravenous lipid infusions replaced the need for TPN.
Conclusions
Children with DGAT1 deficiency respond to dietary restriction of lipids. Management with a novel nutritional approach provides effective treatment for infants with DGAT1 deficiency, treats diarrhea and PLE, promotes growth and development, avoids TPN dependency, and decreases the potential for essential fatty acid deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hadassah, Pediatric Gastroenterology, Jerusalem, Israel.
- Rambam, Pediatric Gastroenterology, Haifa, Israel.
- Kaplan, Pediatric Gastroenterology, Rehovot, Israel.
- Center for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden.
- Mass General Hospital for Children, Pediatric Gastroenterology, Boston, Massachusetts, USA.
Förderung
- None
Zitieren
APA
Millman, P., Rimon, R. M., Toff, C., Engvall, M., Shaoul, R., Wilschanski, M., Elyashar, H., & Winter, H. S. (2024). A novel nutritional approach to infants and children with congenital diarrhea due to homozygous DGAT1 mutations. Journal of Pediatric Gastroenterology and Nutrition, 79(2), 250-258. https://doi.org/10.1002/jpn3.12241
Vancouver
Millman P, Rimon RM, Toff C, Engvall M, Shaoul R, Wilschanski M, et al. A novel nutritional approach to infants and children with congenital diarrhea due to homozygous DGAT1 mutations. Journal of Pediatric Gastroenterology and Nutrition. 2024;79(2):250-258. doi:10.1002/jpn3.12241
BibTeX
@article{Millman2024,
author = {Millman, Peri and Rimon, Ramit M and Toff, Chani and Engvall, Martin and Shaoul, Ron and Wilschanski, Michael and Elyashar, Hila and Winter, Harland S},
title = {A novel nutritional approach to infants and children with congenital diarrhea due to homozygous DGAT1 mutations},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
volume = {79},
number = {2},
pages = {250--258},
doi = {10.1002/jpn3.12241}
}
EUVIMED